U.S. markets close in 3 hours 27 minutes
  • S&P 500

    4,077.12
    -2.99 (-0.07%)
     
  • Dow 30

    34,384.57
    -205.20 (-0.59%)
     
  • Nasdaq

    11,471.69
    +3.70 (+0.03%)
     
  • Russell 2000

    1,878.76
    -7.82 (-0.41%)
     
  • Crude Oil

    82.20
    +1.65 (+2.05%)
     
  • Gold

    1,815.10
    +55.20 (+3.14%)
     
  • Silver

    22.76
    +0.98 (+4.52%)
     
  • EUR/USD

    1.0509
    +0.0101 (+0.97%)
     
  • 10-Yr Bond

    3.5650
    -0.1380 (-3.73%)
     
  • GBP/USD

    1.2257
    +0.0195 (+1.62%)
     
  • USD/JPY

    135.4000
    -2.6800 (-1.94%)
     
  • BTC-USD

    16,976.78
    +193.86 (+1.16%)
     
  • CMC Crypto 200

    402.29
    -3.87 (-0.95%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study

  • Alzamend Neuro Inc (NASDAQ: ALZN) submitted an investigational new drug application to the FDA for its immunotherapy candidate, ALZN002.

  • The product candidate is designed to treat mild to moderate dementia of the Alzheimer's type.

  • ALZN002 is a proprietary "active" immunotherapy product, which means each patient's immune system produces it.

  • It consists of autologous dendritic cells (DCs) that are activated white blood cells taken from each patient so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins.

  • Related: These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win.

  • These DCs are pulsed with a novel amyloid-beta peptide designed to bolster the ability of the patient's immune system to combat Alzheimer's.

  • The ALZN002-01 Phase 1/2A trial will assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer's type.

  • Price Action: ALZN shares are down 6.78% at $1.10 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.